Trimodality bladder preservation therapy for muscle-invasive bladder cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 8, 2013, Pages 952-960

  Chen, Ronald C ^a   Shipley, William U ^b   Efstathiou, Jason A ^b   Zietman, Anthony L ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN; PACLITAXEL; VINBLASTINE;

ARTICLE; BLADDER FUNCTION; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CYSTECTOMY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; LONG TERM SURVIVAL; MORBIDITY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSURETHRAL RESECTION; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIMODALITY BLADDER PRESERVATION THERAPY; UROGENITAL TRACT DISEASE;

CHEMORADIOTHERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; HUMANS; MUSCLE NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84882944773     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0116     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Gray P, Fedewa S, Shipley W, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the united states: results from the National Cancer Data Base. Eur Urol 2013;63:823-829.
3. Lund L, Jacobsen J, Clark P, et al. Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. Urology 2010;75:393-398.
4. Megwalu II, Vlahiotis A, Radwan M, et al. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol 2008;53:581-589.
5. Clark PE, Agarwal N, Eisenberger MA, et al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 1, 2013. Available at: NCCN.org. Accessed July 10, 2013.
6. Gakis G, Efstathiou J, Lerner SP, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial arcinoma of the bladder. Eur Urol 2013;63:45-57.
7. Froehner M, Brausi MA, Herr HW, et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56:443-454.
8. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a highvolume tertiary cancer center experience. Eur Urol 2009;55:177-185.
9. Liberman D, Lughezzani G, Sun M, et al. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology 2011;77:660-666.
10. Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329:1377-1382.
11. Mak R, Hunt D, Shipley W, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: a pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233 [abstract]. J Clin Oncol 2012;30(Suppl 5):Abstract 264.
12. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-711.
13. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-3071.
14. Perdonà S, Autorino R, Damiano R, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008;112:75-83.
15. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477-1488.
16. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-3583.
17. Efstathiou JA, Shipley WU. Words of wisdom. Re: radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Eur Urol 2013;63:181-182.
18. Hussain SA, Moffitt DD, Glaholm JG, et al. A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Ann Oncol 2001;12:929-935.
19. Kent E, Sandler H, Montie J, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 2004;22:2540-2545.
20. Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011;29:733-738.
21. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-866.
22. Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011;186:1261-1268.
23. Gray PJ, Fedewa SA, Shipley WU, et al. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: associations with clinical variables and survival [abstract]. J Clin Oncol 2013;31(Suppl 6):Abstract 248.
24. Malmström PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155:1903-1906.
25. Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatinmethotrexate chemotherapy for invasive bladder cancer - Nordic Cystectomy Trial 2. Scand J Urol Nephrol 2002;36:419-425.
26. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-476.
27. Kaufman DS, Winter KA, Shipley WU, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twicedaily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009;73:833-837.
28. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665-672.
29. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 009;27:4055-4061.
30. Zapatero A, García-Vicente F, Martín de Vidales C, et al. Longterm results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? Int J Radiat Oncol Biol Phys 2011;81:1279-1285.
31. Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97- 015). Int J Radiat Oncol Biol Phys 2011;79:172-178.
32. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170:1772-1776.
33. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-2157.
34. Eswara JR, Efstathiou JA, Heney NM, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol 2012;187:463- 468.
35. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119-126.
36. Zapatero A, Martin de Vidales C, Arellano R, et al. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol 2010;28:368-374.
37. Fung CY, Shipley WU, Young RH, et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol 1991;9:1533-1542.
38. Choudhury A, Nelson LD, Teo MT, et al. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010;70:7017- 7026.
39. Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int 2012;110:E1228-1236.
40. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracilcisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol, in press.